Cel-Sci says it's out of compliance with Amex listing rules after failing to file 10-Q

By Angela McDaniels

Seattle, Feb. 17 - Cel-Sci Corp. said it was unable to file its 10-Q report for the quarter ended Dec. 31 on time and is, therefore, not in compliance with the American Stock Exchange's listing requirements.

The company must submit a plan to the Amex by March 3 describing what actions it will take to file the 10-Q report no later than April 6, according to a company news release.

On Jan. 18, Cel-Sci announced that it would be unable to file its 10-K report for the year ended Sept. 30 by the Jan. 24 deadline.

The company submitted a plan to regain compliance to Amex on Feb. 7 and has until March 20 to file its 10-K report.

Cel-Sci is a pharmaceutical company with operations in Vienna, Va., and Baltimore that develops immune system-based treatments for cancer and infectious diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.